ATE128463T1 - Piperidin und pyrrolidin derivate. - Google Patents

Piperidin und pyrrolidin derivate.

Info

Publication number
ATE128463T1
ATE128463T1 AT90917305T AT90917305T ATE128463T1 AT E128463 T1 ATE128463 T1 AT E128463T1 AT 90917305 T AT90917305 T AT 90917305T AT 90917305 T AT90917305 T AT 90917305T AT E128463 T1 ATE128463 T1 AT E128463T1
Authority
AT
Austria
Prior art keywords
alkyl
pct
formula
group
independently
Prior art date
Application number
AT90917305T
Other languages
English (en)
Inventor
David Alker
Peter Edward Cross
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE128463T1 publication Critical patent/ATE128463T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT90917305T 1990-01-06 1990-11-28 Piperidin und pyrrolidin derivate. ATE128463T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909000301A GB9000301D0 (en) 1990-01-06 1990-01-06 Piperidine & pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
ATE128463T1 true ATE128463T1 (de) 1995-10-15

Family

ID=10668922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90917305T ATE128463T1 (de) 1990-01-06 1990-11-28 Piperidin und pyrrolidin derivate.

Country Status (14)

Country Link
US (1) US5344835A (de)
EP (1) EP0510003B1 (de)
JP (1) JPH0692365B2 (de)
AT (1) ATE128463T1 (de)
CA (1) CA2067758C (de)
DE (1) DE69022744T2 (de)
DK (1) DK0510003T3 (de)
ES (1) ES2078356T3 (de)
FI (1) FI922341A0 (de)
GB (1) GB9000301D0 (de)
GR (1) GR3017944T3 (de)
IE (1) IE69312B1 (de)
PT (1) PT96421B (de)
WO (1) WO1991010650A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB9020051D0 (en) * 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
SK11402000A3 (sk) * 1998-02-04 2001-03-12 Banyu Pharmaceutical Co., Ltd Cyklické n-acylaminoderiváty
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE60011755T2 (de) * 1999-04-07 2005-06-30 The University Of Virginia Patent Foundation Calciumkanalblocker als antikrebsmittel
US8211916B2 (en) * 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
AU2001275537A1 (en) 2000-06-20 2002-01-02 Wayne State University N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
US8017791B2 (en) * 2003-03-28 2011-09-13 Wayne State University Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
WO2005087763A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
US7071224B2 (en) * 2004-03-11 2006-07-04 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
JP2007532672A (ja) 2004-04-16 2007-11-15 ウェイン ステート ユニバーシティ 三置換２−ベンズヒドリル−５−ベンジルアミノ−テトラヒドロ−ピラン−４−オール、及び６−ベンズヒドリル−４−ベンジルアミノ−テトラヒドロ−ピラン−３−オール類縁体、及び新規３，６−二置換ピラン誘導体
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE934890C (de) * 1951-10-07 1955-11-10 Chem Fab Promonta Ges Mit Besc Verfahren zur Herstellung von basischen Benzhydrylaethern
GB780027A (en) * 1955-01-20 1957-07-31 Schering Corp 3-piperidyl ethers and thioethers
US2974146A (en) * 1956-02-24 1961-03-07 Lakeside Lab Inc 3-piperidyl benzhydryl ethers
US4810713A (en) * 1985-12-20 1989-03-07 A. H. Robins Company, Incorporated Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
EP0235463A3 (de) * 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) N-substituierte Arylalkyl- und Arylalkylen-Piperidine und Anwendung als kardiovaskulär antihistaminische und antisekretorische Mittel
GB8816365D0 (en) * 1988-07-08 1988-08-10 Pfizer Ltd Therapeutic agents
EP0370629B2 (de) * 1988-11-21 1998-01-07 Zeneca Limited Fungizide

Also Published As

Publication number Publication date
DK0510003T3 (da) 1996-01-29
JPH05501560A (ja) 1993-03-25
CA2067758A1 (en) 1991-07-07
GR3017944T3 (en) 1996-02-29
FI922341A7 (fi) 1992-05-22
PT96421A (pt) 1991-10-15
DE69022744D1 (de) 1995-11-02
JPH0692365B2 (ja) 1994-11-16
FI922341L (fi) 1992-05-22
EP0510003B1 (de) 1995-09-27
DE69022744T2 (de) 1996-03-07
FI922341A0 (fi) 1992-05-22
PT96421B (pt) 1997-05-28
EP0510003A1 (de) 1992-10-28
IE69312B1 (en) 1996-09-04
ES2078356T3 (es) 1995-12-16
GB9000301D0 (en) 1990-03-07
WO1991010650A1 (en) 1991-07-25
IE910020A1 (en) 1991-07-17
US5344835A (en) 1994-09-06
CA2067758C (en) 1994-12-13

Similar Documents

Publication Publication Date Title
DE69022744D1 (de) Piperidin und pyrrolidin derivate.
DE69014901D1 (de) Muscarin-rezeptor-antagonisten.
TW369526B (en) Diazabicyclic neurokinin antagonists
EP1679069A4 (de) Neues piperidinderivat
DE69815161D1 (de) Azindolethylaminderivate als Nikotin-acetylcholin-Rezeptor Bindung Verbindungen
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
TR200102789T2 (tr) Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
ATE64373T1 (de) Muscarin-rezeptor-antagonisten.
FI955387A0 (fi) 4(p-fluorifenyyli)-3-((3,4-(metyleenioksi)fenoksi)metyyli)-piperidiinin N-p-halobentsoyylimetyylijohdannaiset
MY123373A (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
ATE42747T1 (de) N-(2-(tetrahydro-3,5-dioxo-1h-pyrrolizin-7a(5h) yl)ethyl>aminderivate.
KR960007560A (ko) 신규한 아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
DK0505379T3 (da) Muscarin-receptor-antagonister
ATE383343T1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
DE69532187D1 (de) Abeo-ergolinderivate als 5ht1a liganden
TNSN06337A1 (en) 6-substituted pyridoindolone derivatives production and therapeutic use thereof
EP0798304A4 (de) Medikamente gegen trhombocytopenie
CA2069931A1 (en) Muscarinic receptor antagonists
SE9901237D0 (sv) Novel use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee